Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
John N GaetanoSection of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago Hospitals, Chicago, IL, USAAbstract: Greater understanding of the hepatitis C virus (HCV) genome and life cycle of the HCV virion allows for new targets for therapy that directly act o...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-03-01
|
| Series: | Drug, Healthcare and Patient Safety |
| Online Access: | http://www.dovepress.com/benefitndashrisk-assessment-of-new-and-emerging-treatments-for-hepatit-a16279 |